ライフサイエンスコーパス: fluorine-18

1 The most recent of these are labeled with fluorine-18.

2 olabeling with the positron-emitting isotope fluorine-18.

3 .83 nM) were selected for radiolabeling with fluorine-18.

4 emission tomography if they are labeled with fluorine-18.

5 cells and suitability for radiolabeling with fluorine-18.

6 scaffolds that were yet to be labelled with fluorine-18.

7 s that are labeled with both fluorescein and fluorine-18.

8 with a positron-emitter, either carbon-11 or fluorine-18.

9 ssion tomographic (PET) radiopharmaceutical, fluorine 18 ((18)F) 2-fl uoropropionyl labeled PEGylated

10 mer's Disease Neuroimaging Initiative (ADNI) fluorine 18 ((18)F) florbetapir (FBP) data set.

11 dient-echo MRI was performed to quantify MH, fluorine 18 ((18)F) flortaucipir (AV-1451) PET was perfo

12 Background National guidelines endorse fluorine 18 ((18)F) fluciclovine PET/CT for the detectio

13 tudy, a public NSCLC data set that contained fluorine 18 ((18)F) fluoro-2-deoxyglucose positron emiss

14 malignant brain lesions can be depicted with fluorine 18 ((18)F) fluorocholine positron emission tomo

15 mals were then injected with (99m)Tc ECDG or fluorine 18 ((18)F) fluorodeoxyglucose (FDG) (0.037-0.07

16 s) were compared with those of animals given fluorine 18 ((18)F) fluorodeoxyglucose (FDG) (n = 15, al

17 Purpose To compare fluorine 18 ((18)F) fluorodeoxyglucose (FDG) combined po

18 ures of tumor metabolism and perfusion using fluorine 18 ((18)F) fluorodeoxyglucose (FDG) dedicated b

19 cyte-M-CSF (GM-CSF) and its implications for fluorine 18 ((18)F) fluorodeoxyglucose (FDG) imaging of

20 sessment of tissue-specific insulin-mediated fluorine 18 ((18)F) fluorodeoxyglucose (FDG) influx rate

21 Fluorine 18 ((18)F) fluorodeoxyglucose (FDG) PET and fol

22 derwent MRI, and four participants underwent fluorine 18 ((18)F) fluorodeoxyglucose (FDG) PET imaging

23 D), mild cognitive impairment, or neither at fluorine 18 ((18)F) fluorodeoxyglucose (FDG) PET of the

24 ke in specific brain regions, detected using fluorine 18 ((18)F) fluorodeoxyglucose (FDG) PET, is a v

25 th tumors who underwent clinically warranted fluorine 18 ((18)F) fluorodeoxyglucose (FDG) PET/CT foll

26 Fluorine 18 ((18)F) fluorodeoxyglucose (FDG) PET/CT has

27 y advanced breast cancer initially staged at fluorine 18 ((18)F) fluorodeoxyglucose (FDG) PET/CT or a

28 rpose To investigate the prognostic value of fluorine 18 ((18)F) fluorodeoxyglucose (FDG) PET/CT para

29 a using contemporary whole-body (WB) MRI and fluorine 18 ((18)F) fluorodeoxyglucose (FDG) PET/CT prot

30 f the left breast, bilateral breast MRI, and fluorine 18 ((18)F) fluorodeoxyglucose (FDG) PET/CT were

31 the chest without contrast enhancement, and fluorine 18 ((18)F) fluorodeoxyglucose (FDG) PET/CT.

32 onents of glucose metabolism, exemplified by fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron em

33 Purpose To assess whether dynamic fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron em

34 e the performance characteristics of interim fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron em

35 Computed tomography (CT), fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron em

36 (CT) of the chest, abdomen, and pelvis; and fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron em

37 The most frequently used tracer, fluorine 18 ((18)F) fluorodeoxyglucose (FDG), is applied

38 iodine studies, as well as PET studies using fluorine 18 ((18)F) fluorodeoxyglucose, gallium 68 ((68)

39 ance and correlation with tumor viability of fluorine 18 ((18)F) fluoromisonidazole (FMISO) uptake in

40 Purpose To determine whether fluorine 18 ((18)F) fluorothymidine (FLT) PET imaging al

41 Fluorine 18 ((18)F) fluorthanatrace ((18)F-FTT) is a PET

42 that positron emission tomography (PET) with fluorine 18 ((18)F) fluorthanatrace (FTT) depicts activa

43 d finding that was further investigated with fluorine 18 ((18)F) flurodeoxyglucose (FDG) positron emi

44 identify quantitative imaging biomarkers at fluorine 18 ((18)F) positron emission tomography (PET) f

45 Purpose To investigate whether fluorine 18 ((18)F) prostate-specific membrane antigen (

46 icipants also underwent translocator protein fluorine 18 ((18)F)-DPA-714 PET for neuroinflammation.

47 Purpose Fluorine 18 ((18)F)-fluciclovine and prostate-specific m

48 ogic outcome in these patients compared with fluorine 18 ((18)F)-fluorocholine and (18)F-PSMA-1007 PE

49 Background Fluorine 18 ((18)F)-fluorodeoxyglucose (FDG) PET/CT is a

50 2025, participants with PSMA-avid disease at fluorine 18 ((18)F)-piflufolastat PET/CT performed withi

51 Molecules labeled with fluorine-18 ((18)F) are used in positron emission tomogr

52 Radiolabeling with fluorine-18 ((18)F) facilitated production of 2-(5,7-die

53 dy, we have synthesized labeled AVT-011 with fluorine-18 ((18)F) followed by in-vitro and in-vivo ana

54 Among the beta(+)-emitting radionuclides, fluorine-18 ((18)F) is the isotope of choice for PET, an

55 The unnatural isotope fluorine-18 ((18)F) is used as a positron emitter in mol

56 eutical agents were efficiently labeled with fluorine-18 ((18)F) or carbon-11 ((11)C).

57 zed alkyl Heck reaction as a mild and robust fluorine-18 ((18)F) radiochemical approach for positron

58 h possibilities have accelerated progress in fluorine-18 ((18)F) radiochemistry with numerous methods

59 antigen (PSMA) with gallium-68 ((68)Ga) and fluorine-18 ((18)F) radiotracers has aroused tremendous

60 Here, we disclose a mild method for the fluorine-18 ((18)F)-fluorination of aromatic C-H bonds b

61 An optimized procedure for preparing fluorine-18 ((18)F)-labeled peptides by the copper-catal

62 usefulness of fluorodesoxyglucose marked by fluorine-18 ((18)F-FDG) positron emission tomography (PE

63 We compared fluorine-18 [(18)F]-Florbetapir uptake in the 5xFAD brai

64 an amyloid PET scan with 1 of 3 AB tracers (fluorine 18 [18F]-labeled florbetapir, 18F-labeled florb

65 Fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) positron em

66 chest wall, and mediastinum were filled with fluorine-18 activities based on the average radionuclide

67 tsburgh Compound-B, the 110 min half-life of fluorine-18 allows for wider utilization in research and

68 thesis, and biological characterization of a fluorine-18 analog of dasatinib, a multitargeted kinase

69 ty were synthesized (4, 5, and 6), and their fluorine-18 analogs were evaluated for use as positron e

70 The fluorine-18 analogue was prepared via nucleophilic subst

71 000) and was selected for radiolabeling with fluorine-18 and biological characterization.

72 9 photo-mediated radiochemistry differs from fluorine-18 and carbon-11 approaches.

73 d probes were labeled with the radioisotopes fluorine-18 and tritium, as well as a fluorescent tag.

74 galectin-3 inhibitors were radiolabeled with fluorine-18 and used as surrogate PET tracers of TD139 a

75 imaging (positron emission tomography (PET)/fluorine-18) and treatment (targeted radionuclide therap

76 nd successfully radiolabeled with carbon-11, fluorine-18, and gallium-68.

77 Two of them were radiolabeled with fluorine-18, and their biodistribution was investigated

78 These compounds were radiolabeled with fluorine-18, and their biological properties were evalua

79 Molecules labeled with fluorine-18 are used as radiotracers for positron emissi

80 olecules labelled with the unnatural isotope fluorine-18 are used for positron emission tomography.

81 zinone derivatives labeled with carbon-11 or fluorine-18 as PDE5-specific PET tracers.

82 , are particularly challenging to label with fluorine-18 because they are densely functionalized and

83 Fluorine-18-BPA-Fr PET is capable of providing in vivo B

84 ize aromatic substrates with the radioactive fluorine-18 but its scope is restricted to arenes contai

85 riven radiochemistry for three key isotopes: fluorine-18, carbon-11, and zirconium-89, and their appl

86 acid (N-MeFAMP), have been radiolabeled with fluorine-18, characterized in amino acid uptake assays,

87 Fluorine-18 could be installed as desired at the 3'-phen

88 ase detection rate of PSMA-based PET/CT with fluorine 18-DCFPyL as a radiotracer and the PET-directed

89 We evaluated the ability of fluorine-18 deoxyglucose positron emission tomography (F

90 Positron emission tomography with fluorine-18-deoxyglucose (FDG-PET) detects active lympho

91 Radioisotopes of fluorine ((18)F), scandium ((43/44)Sc, (47)Sc), lutetium

92 months after vaccination, including cardiac fluorine 18 FDG PET/MRI, blood biomarkers, and health-re

93 Fluorine-18-FDG was administered to 18 Parkinson's disea

94 ated with focused ultrasound, as measured by fluorine-18 florbetaben positron-emission tomography.

95 als, to compare PSMA to other agents such as fluorine 18 fluciclovine and carbon 11 choline, and to h

96 cer is preferably performed with PET using 2-fluorine 18-fluoro-2-deoxy-d-glucose ((18)F-FDG).

97 nts analysis (PCA) was applied to dynamic 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) positron emis

98 e introduced on non-attenuation-corrected 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) positron emis

99 Hepatic 2-[fluorine-18]fluoro-2-deoxy-D-glucose uptake associated w

100 Hepatic 2-[fluorine-18]fluoro-2-deoxy-D-glucose uptake associated w

101 phy angiography), those with high hepatic 2-[fluorine-18]fluoro-2-deoxy-D-glucose uptake had higher n

102 e subtypes in PET measurements of 2-deoxy-2-[fluorine-18]fluoro-D-glucose ([(18)F]FDG) uptake.

103 obtained after administration of 2-deoxy-2-[fluorine-18]fluoro-D-glucose in 39 patients with probabl

104 ith micro-PET by using the radiotracer 9-(4-[fluorine 18]-fluoro-3-hydroxymethylbutyl)-guanine (FHBG)

105 PET imaging of malignant tumors with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) as a tracer

106 The utility of 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission

107 minutes after injection of 370 MBq (10 mCi) fluorine 18 fluorodeoxyglucose ((18)F-FDG) followed by p

108 analysis, the role of metabolic imaging with fluorine 18 fluorodeoxyglucose (FDG) in breast cancer is

109 lculation of the percentage injected dose of fluorine 18 fluorodeoxyglucose (FDG) in tumor from small

110 PET with the labeled glucose analogue fluorine 18 fluorodeoxyglucose (FDG) is a relatively rec

111 out tumor metabolism, which is measured with fluorine 18 fluorodeoxyglucose (FDG) PET.

112 s and possible CS who were investigated with fluorine 18 fluorodeoxyglucose (FDG) PET/CT and cardiac

113 lly suspected underwent clinically indicated fluorine 18 fluorodeoxyglucose (FDG) PET/CT and, immedia

114 and to identify differences between WAT and fluorine 18 fluorodeoxyglucose (FDG) PET/CT proven cold-

115 baseline magnetic resonance (MR) imaging and fluorine 18 fluorodeoxyglucose (FDG) positron emission t

116 Fluorine 18 fluorodeoxyglucose (FDG) positron emission t

117 ively compare the sensitivity of a dedicated fluorine 18 fluorodeoxyglucose (FDG) positron emission t

118 luate the positive predictive value (PPV) of fluorine 18 fluorodeoxyglucose (FDG) positron emission t

119 aging technique in body imaging is currently fluorine 18 fluorodeoxyglucose (FDG) positron emission t

120 he correlation between metabolic activity at fluorine 18 fluorodeoxyglucose (FDG) positron emission t

121 Purpose To assess the diagnostic accuracy of fluorine 18 fluorodeoxyglucose (FDG) positron emission t

122 It has been reported that fluorine 18 fluorodeoxyglucose (FDG) positron emission t

123 he established patterns of hypometabolism on fluorine 18 fluorodeoxyglucose (FDG) positron emission t

124 trinsic contrast of melanin in comparison to fluorine 18 fluorodeoxyglucose (FDG) positron emission t

125 cal-pathologic nodal status with use of four fluorine 18 fluorodeoxyglucose (FDG) positron emission t

126 ss significant (P < .05) differences between fluorine 18 fluorodeoxyglucose (FDG) uptake of benign le

127 Fluorine 18 fluorodeoxyglucose (FDG) was mixed with diff

128 acilitate future direct correlations between fluorine 18 fluorodeoxyglucose (FDG)-avid colonic lesion

129 ts suspected of having abdominal or thoracic fluorine 18 fluorodeoxyglucose (FDG)-positive lesions un

130 and consists of imaging the distribution of fluorine 18 fluorodeoxyglucose (FDG).

131 phic (CT) and (18)F-fluorodeoxyglucose ( FDG fluorine 18 fluorodeoxyglucose ) PET/CT examinations wer

132 Histograms of administered activity for fluorine 18 fluorodeoxyglucose and iodine 131 sodium iod

133 aging, and positron emission tomography with fluorine 18 fluorodeoxyglucose and novel tracers.

134 ermined with findings of decreased uptake of fluorine 18 fluorodeoxyglucose at PET, shrinkage of tumo

135 olving a labeled dose of 370 MBq (10 mCi) of fluorine 18 fluorodeoxyglucose is estimated to involve a

136 nt contrast material-enhanced MR imaging and fluorine 18 fluorodeoxyglucose PEM in randomized order;

137 y (PET) and coregistered computed tomography/fluorine 18 fluorodeoxyglucose PET are used primarily in

138 rials and Methods Between 2010 and 2013, 219 fluorine 18 fluorodeoxyglucose PET examinations were per

139 etail methods for controlling the quality of fluorine 18 fluorodeoxyglucose PET imaging conditions to

140 Conclusion By using fluorine 18 fluorodeoxyglucose PET of the brain, a deep

141 public data set of multimodality images (CT, fluorine 18 fluorodeoxyglucose PET, and T1-weighted MRI)

142 s gallium 68 DOTA-Tyr3-octreotide PET/CT and fluorine 18 fluorodeoxyglucose PET, play an increasing r

143 t (Fig 1), bilateral breast MRI (Fig 2), and fluorine 18 fluorodeoxyglucose PET/CT (Fig 3) were perfo

144 st without contrast enhancement (Fig 3), and fluorine 18 fluorodeoxyglucose PET/CT (Fig 4).

145 l of 30 lesions were evaluated at (18)F- FDG fluorine 18 fluorodeoxyglucose PET/CT and (18)F- FPPRGD2

146 ure to compare the diagnostic performance of fluorine 18 fluorodeoxyglucose PET/CT and diffusion-weig

147 5 years) who underwent health screening with fluorine 18 fluorodeoxyglucose PET/CT between January 20

148 xaminations, as well as clinically indicated fluorine 18 fluorodeoxyglucose PET/CT examination within

149 trointestinal malignancies underwent two FDG fluorine 18 fluorodeoxyglucose PET/CT examinations withi

150 n lesions presents a further challenge where fluorine 18 fluorodeoxyglucose PET/CT has a potential ro

151 ted MRI is comparable or superior to that of fluorine 18 fluorodeoxyglucose PET/CT in the differentia

152 Conclusion Baseline fluorine 18 fluorodeoxyglucose PET/CT metabolic tumor vo

153 Two hundred eighty-two fluorine 18 fluorodeoxyglucose PET/CT studies in 75 pedi

154 background is recommended in multicenter FDG fluorine 18 fluorodeoxyglucose PET/CT studies on the bas

155 serial cross-sectional imaging (CT, MRI, or fluorine 18 fluorodeoxyglucose PET/CT) between April 201

156 -grade tumors, they were also evaluated with fluorine 18 fluorodeoxyglucose PET/CT, with imaging find

157 nderwent preoperative metabolic imaging with fluorine 18 fluorodeoxyglucose PET/CT.

158 ighted MRI showed significant agreement with fluorine 18 fluorodeoxyglucose PET/MRI for treatment res

159 ndmark finding relied on the use of clinical fluorine 18 fluorodeoxyglucose positron emission tomogra

160 Fluorine 18 fluorodeoxyglucose positron emission tomogra

161 es after injection, compared with (18)F- FDG fluorine 18 fluorodeoxyglucose uptake with SUVmax maximu

162 2.3) at 60 minutes, compared with (18)F- FDG fluorine 18 fluorodeoxyglucose uptake with SUVmax maximu

163 patients (20.7%) with adequate follow-up had fluorine 18 fluorodeoxyglucose-avid IMLN, with a median

164 CT scans is feasible and may be helpful when fluorine 18 fluorodeoxyglucose-avid masses that are not

165 ough positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ((18)F-FDG) has a major i

166 al (IB) routes and imaged sequentially using fluorine-18 fluorodeoxyglucose ((18)FDG) uptake as a non

167 y (PET) using nitrogen-13 (N-13) ammonia and fluorine-18 fluorodeoxyglucose (FDG) for imaging of perf

168 pectively investigated the value of PET with fluorine-18 fluorodeoxyglucose (FDG) for preoperative ch

169 hat positron emission tomography (PET) using fluorine-18 fluorodeoxyglucose (FDG) may be useful for d

170 ing optimal interpretative criteria (IC) for Fluorine-18 fluorodeoxyglucose (FDG) Positron Emission T

171 , and two underwent gallium scintigraphy and fluorine-18 fluorodeoxyglucose (FDG) positron emission t

172 a marker for tissue viability with regional fluorine-18 fluorodeoxyglucose (FDG) uptake in patients

173 Fluorine-18 fluorodeoxyglucose (FDG) with positron emiss

174 There seems to be emerging roles for fluorine-18 fluorodeoxyglucose (FDG)-PET, laparoscopic s

175 The prognostic utility of midtreatment fluorine-18 fluorodeoxyglucose positron emission tomogra

176 Fluorine-18 fluorodeoxyglucose positron emission tomogra

177 Functional metabolic imaging through fluorine-18 fluorodeoxyglucose positron emission tomogra

178 erapy with both computed tomography (CT) and fluorine-18 fluorodeoxyglucose positron emission tomogra

179 hereas vascular inflammation was assessed by fluorine-18 fluorodeoxyglucose uptake on positron emissi

180 (molecular biology) and imaging diagnostic (fluorine-18 fluorodeoxyglucose-positron emission tomogra

181 ing of malignancy, bone marrow activity from fluorine 18-fluorodeoxyglucose (FDG) PET may be informat

182 onclusion A model that includes pretreatment fluorine 18-fluorodeoxyglucose PET texture features from

183 anatomic localization and classification of fluorine 18-fluorodeoxyglucose PET uptake patterns in fo

184 d 20 nonsmoking control subjects underwent 2 fluorine 18-fluorodeoxyglucose positron emission tomogra

185 We visually compared fluorine-18-fluorodeoxyglucose (FDG)-PET images to radio

186 rves (TACs) from mouse PET studies done with fluorine-18-fluorodeoxyglucose (FDG).

187 Fluorine-18-fluorodeoxyglucose detected unsuspected meta

188 Fluorine-18-fluorodeoxyglucose imaging was more accurate

189 Fluorine-18-fluorodeoxyglucose PET/CT imaging detects tr

190 tudy was to evaluate the prognostic value of fluorine-18-fluorodeoxyglucose PET/CT imaging of venous

191 The accuracy of fluorine-18-fluorodeoxyglucose positron emission tomogra

192 magnetic resonance imaging and angiography, fluorine-18-fluorodeoxyglucose positron emission tomogra

193 ed to segment and quantify serial changes in fluorine-18-fluorodeoxyglucose uptake for veins of inter

194 s, positron emission tomography imaging with fluorine-18-fluorodeoxyglucose, and cardiac magnetic res

195 changes in lower extremity venous uptake of fluorine-18-fluorodeoxyglucose.

196 ing positron emission tomography (PET) with [fluorine-18]fluorodopa (F18-DOPA), we compared the integ

197 l applications of ER-targeting imaging using fluorine 18 fluoroestradiol PET.

198 Cholinergic levels were measured using fluorine-18 fluoroethoxybenzovesamicol (18F-FEOBV) PET i

199 Fluorine-18 flurpiridaz is a novel positron emission tom

200 nium-mediated uronium deoxyfluorination with fluorine-18 followed by deprotection, accomplished withi

201 sthetic group was synthesized to incorporate fluorine-18 for PET imaging.

202 Fluorine-18-FPCIT showed a striatum-to-occipital ratio (

203 Fluorine-18-FPH appears to be a suitable tracer to study

204 Fluorine-18-FPH labels nAChR in vivo in the mouse brain.

205 Fluorine-18-FPH was administered intravenously to mice,

206 Fluorine-18-FTHA EF paralleled the changes in beta-oxida

207 lled modular build-up approach), introducing fluorine-18 in a fast and efficient manner in a building

208 by late-stage radiofluorination, introducing fluorine-18 in the last step of the synthesis, or by a b

209 Compounds 3a and 6a were radiolabeled with fluorine-18 in two steps and utilized in positron emissi

210 for SULT1E1 can be labeled with carbon-11 or fluorine-18, in vivo assays of SULT1E1 functional activi

211 Fluorine-18 is the most frequently used radioisotope in

212 Fluorine-18 is the most widely used PET-radionuclide and

213 Fluorine-18 is the most widely used radioisotope for PET

214 dopamine synthesis capacity was measured by fluorine-18-l-dihydroxyphenylalanine (F-18-FDOPA) positr

215 [(18)F]tetrabutylammonium fluoride to afford fluorine-18 labeled (hetero)arenes in high radiochemical

216 Herein, we synthesized a fluorine-18 labeled d-fluoroalanine, d-3-[(18)F]fluoroal

217 rves to activate either the substrate or the fluorine-18 labeled reagent.

218 he purpose of this study was to synthesize a fluorine-18 labeled, highly selective aldosterone syntha

219 pairment aged 65 to 85 years who completed a fluorine 18-labeled (18F)-florbetapir positron emission

220 Fluorine 18-labeled ASEM ([18F] ASEM) PET data were acqu

221 Exposures: Imaging with fluorine 18-labeled AV-1451 ([18F]AV-1451) (formerly kno

222 orylated tau pathologic findings measured by fluorine 18-labeled AV-1451 ([18F]AV-1451) positron emis

223 emission tomography imaging with radiotracer fluorine 18-labeled florbetapir.

224 here have been conflicting results regarding fluorine 18-labeled fluorodeoxyglucose ((18)F-FDG) PET/M

225 Conclusion Fluorine 18-labeled fluorodeoxyglucose ((18)F-FDG) PET/M

226 Inflammatory cells have avidity for fluorine 18-labeled fluorodeoxyglucose ((18)F-FDG), and

227 o undergo low-dose PEM with up to 185 MBq of fluorine 18-labeled fluorodeoxyglucose ((18)F-FDG).

228 Assessment with fluorine 18-labeled fluorodeoxyglucose (18F-FDG) positro

229 Fluorine 18-labeled fluoromisonidazole ([18F]FMISO), a P

230 ositron emission tomography with radioligand fluorine 18-labeled setoperone as the tracer.

231 Background MRI and fluorine 18-labeled sodium fluoride ((18)F-NaF) PET can

232 Conclusion Fluorine 18-labeled sodium fluoride PET/MRI characterist

233 aracteristics, AB burden (as measured with a fluorine 18-labeled-florbetapir PET scan), objective and

234 amyloid positron emission tomography (PET); fluorine 18-labeled-fluorodeoxyglucose PET; and/or magne

235 Fluorine-18-labeled 2 beta-carbomethoxy-3 beta-(4-chloro

236 x (10(6) p/s/cm(2)/sr)] but similar level of fluorine-18-labeled 2'-fluoro-2'-deoxyarabinofuranosyl-5

237 ic positron emission tomography imaging with fluorine-18-labeled 2-fluoro-2-deoxyglucose ((18)FDG) li

238 1, and glycolytic genes, hk1 and pdk1, lung fluorine-18-labeled 2-fluoro-2-deoxyglucose ligand uptak

239 foundation for the future construction of a fluorine-18-labeled 5-ALA PET tracer to be used for func

240 her accumulation (P < 0.05) of 18F-FEAU than fluorine-18-labeled 9-(4-fluoro-3-hydroxymethylbutyl)gua

241 Existing fluorine-18-labeled amino acid-based radiotracers predom

242 itron emission tomography (PET) imaging with fluorine-18-labeled androgens.

243 We present fluorine-18-labeled fluorocarfentanils ([(18)F]FCFNs), w

244 p-tau181 and NfL measurements and at least 1 fluorine-18-labeled fluorodeoxyglucose (FDG) positron em

245 Although inflammation can be measured using fluorine-18-labeled fluorodeoxyglucose positron emission

246 based labeling method was used to synthesize fluorine-18-labeled insulin specifically B(1)-(4-[(18)F]

247 on, we first developed a small peptide-based fluorine-18-labeled PET imaging agent, [(18)F]DK222, whi

248 In the search for an optimal fluorine-18-labeled positron emission tomography (PET) r

249 cross-linking noninvasively, we developed a fluorine-18-labeled positron emission tomography agent (

250 It is likely that more than one fluorine-18-labeled tracer will come into common use.

251 The fluorine-18-labeled tracers successfully differentiated

252 Fluorine-18 labeling of favipiravir was achieved in a on

253 Prior to fluorine-18 labeling, the nonradioactive fluoro derivati

254 pha-tertiary haloamides to the corresponding fluorine-18 labelled alpha-tertiary fluoroamides with no

255 overview of the synthesis and application of fluorine-18 labelled building blocks since 2010.

256 lucose homeostasis was studied in mice using fluorine-18 labelled glucose molecular imaging probes an

257 or selection of a synthetic approach for new fluorine-18 labelled PET tracers.

258 Further advances are being made with other fluorine-18-labelled and generator-based PET tracers, th

259 After injection with fluorine-18-labelled fluorodeoxyglucose, patients underw

260 tumour and normal-tissue pharmacokinetics of fluorine-18-labelled fluorouracil.

261 eatures but uncertain clinical diagnosis had fluorine-18-labelled-fluorodeoxyglucose-PET at The Feins

262 de scaffold to facilitate radiolabeling with fluorine-18 or carbon-11 positron-emitting nuclides and

263 [(18)F]PF-NB1 is a promising fluorine-18 PET tracer for imaging the GluN2B subunits o

264 Fluorine-18-PFBG is specifically accumulated by sympathe

265 Fluorine-18-PFBG was administered to working rat hearts

266 temetamol injection labeled with radioactive fluorine 18 positron emission tomography imaging for bra

267 (PTC) (e.g. kryptofix 2.2.2) associated with fluorine-18 preparation has been found to be detrimental

268 l molecules, peptides, and proteins with the fluorine-18 prosthetic [(18)F]4-fluorophenylboronic acid

269 The new procedures are effective for fluorine-18 radiochemistry and, as proof of concept, hav

270 challenging to synthesize using traditional fluorine-18 radiochemistry.

271 series of candidates, radiolabeled them with fluorine-18 radioisotope, and determined their physicoch

272 for the lead compound PEGMeDAS and automated fluorine-18 radiolabeling afforded [(18)F]PEGMeDAS in 25

273 Fluorine-18 radiolabeling typically includes several con

274 Fluorine-18 remains the most widely clinically utilized

275 4), magnetic resonance imaging (n = 3), and fluorine-18 sodium fluoride positron emission tomography

276 PET and SPECT, with fluorine-18 sodium fluoride, were performed sequentially

277 Compound 9 was labeled with fluorine-18 (t(1/2) = 109.7 min) in high specific activi

278 ter, either carbon-11 (t(1/2) = 20.4 min) or fluorine-18 (t(1/2) = 109.7 min), and included (i) repla

279 Fluorine-18 (t(1/2) = 109.8 min) is a major radionuclide

280 Cyclotron-produced short-lived fluorine-18 (t(1/2) = 109.8 min) is widely used to radio

281 and benefiting from the longer half-life of fluorine-18 (t(1/2) = 109.8 min), facilitating broader a

282 with either carbon-11 (t(1/2) = 20.4 min) or fluorine-18 (t(1/2) = 109.8 min), so allowing the append

283 Fluorine-18 (t(1/2)=109.7 min) is the most commonly used

284 Compound 3 was labeled with fluorine-18 (t1/2 = 109.7 min) in high radiochemical yie

285 ctively targeting the ghrelin receptor using fluorine-18 tagged entities would allow localization and

286 In the case of fluorine-18, the predominant approach involves the use o

287 f thioethers to be labeled with carbon-11 or fluorine-18 through S-alkylation reactions.

288 Both were radiolabeled with fluorine-18 using a copper-mediated method.

289 -1 (sigma1) receptors were radiolabeled with fluorine-18 via displacement of the corresponding mesyla

290 temetamol injection labeled with radioactive fluorine 18 (Vizamyl; GE Healthcare) administration foll

291 temetamol injection labeled with radioactive fluorine 18 was safe and had high sensitivity and specif

292 Incorporation of fluorine-18 was achieved by nucleophilic displacement of

293 Fluorine-18 was introduced into 2 beta-carbomethoxy-3 be

294 y of nucleophilic aromatic substitution with fluorine-18, we describe two complementary procedures fo

295 Nanoparticles containing fluorine-18 were prepared from block copolymers made by